Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...
Novo Holdings, the controlling shareholder of Novo Nordisk, on Wednesday sealed its $16.5 billion deal for Catalent, as the ...
Novo Holdings has completed the previously announced acquisition of Catalent in a $16.5bn all-cash transaction. The European ...
The Series C – which was led by Novo Nordisk's parent company Novo Holdings – follows a $15 million second round for the ...
UPDATE: The European Commission unconditionally approved Novo Holdings’ takeover of Catalent on Friday. The deal still will need Federal Trade Commission approval. Years of layoffs and alleged ...
BRUSSELS (Reuters) -Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any ...
Novo Nordisk plans to buy from the holding company three sites — Brussels; Anagni, Italy; and Bloomington — for $11.7 billion ...
The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of Novo Nordisk, one of the largest pharmaceutical companies, would pay $ ...
Dec 18 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, on Wednesday sealed its $16.5 billion deal for Catalent (CTLT.N), opens new tab ...
Novo Nordisk will soon acquire from Novo Holdings Catalent’s three fill-finish sites located in Italy, the U.S., and Belgium.
BRUSSELS, Dec 6 (Reuters) - Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent (CTLT.N), opens new tab after EU ...